POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS

被引：1
|
作者：
Dorner, T. [1 ]
Tanaka, Y. [2 ]
Mosca, M. [3 ]
Bruce, I. N. [4 ]
Cardiel, M. [5 ]
Morand, E. F. [6 ]
Petri, M. A. [7 ]
Silk, M. [8 ]
Dickson, C. [8 ]
Meszaros, G. [8 ]
Issa, M. [8 ]
Zhang, L. [8 ]
Wallace, D. J. [9 ]
机构：
[1] Charite, Med Rheumatol & Clin Immunol, Berlin, Germany
[2] Univ Occupat & Environm Hlth, First Dept Internal Med, Kitakyushu, Fukuoka, Japan
[3] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[4] Univ Manchester, Div Musculoskeletal & Dermatol Sci, Manchester, Lancs, England
[5] Centro Investigac Clin Morelia, Clinical Res, Morelia, Michoacan, Mexico
[6] Monash Univ, Ctr Inflammatory Dis, Melbourne, Vic, Australia
[7] Johns Hopkins Univ, Div Rheumatol, Baltimore, MD USA
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Rheumatol Allergy & Immunol, Los Angeles, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.2375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0714
引用
收藏
页码：639 / 639
页数：1
相关论文
共 50 条
  • [31] Hepatic safety of galcanezumab in patients with migraine: Results of three Phase 2 double-blind placebo-controlled trials
    Regev, Arie
    Camporeale, Angelo
    Skljarevski, Vladimir
    Wang, Shufang
    Carter, Jeff
    NEUROLOGY, 2017, 88
  • [32] Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials
    Papp, Kim A.
    Armstrong, April W.
    Reich, Kristian
    Karunaratne, Mahinda
    Valdecantos, Wendell
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2016, 17 (01) : 79 - 86
  • [33] Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials
    Kim A. Papp
    April W. Armstrong
    Kristian Reich
    Mahinda Karunaratne
    Wendell Valdecantos
    American Journal of Clinical Dermatology, 2016, 17 : 79 - 86
  • [34] Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials
    Goodman, WK
    Bose, A
    Wang, Q
    JOURNAL OF AFFECTIVE DISORDERS, 2005, 87 (2-3) : 161 - 167
  • [35] Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
    Furie, Richard A.
    Hough, Douglas R.
    Gaudy, Allison
    Ye, Ying
    Korish, Shimon
    Delev, Nikolay
    Weiswasser, Michael
    Zhan, Xiaojiang
    Schafer, Peter H.
    Werth, Victoria P.
    LUPUS SCIENCE & MEDICINE, 2022, 9 (01):
  • [36] Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
    He, Jing
    Zhang, Ruijun
    Shao, Miao
    Zhao, Xiaozhen
    Miao, Miao
    Chen, Jiali
    Liu, Jiajia
    Zhang, Xiaoying
    Zhang, Xia
    Jin, Yuebo
    Wang, Yu
    Zhang, Shilei
    Zhu, Lei
    Jacob, Alexander
    Jia, Rulin
    You, Xujie
    Li, Xue
    Li, Chun
    Zhou, Yunshan
    Yang, Yue
    Ye, Hua
    Liu, Yanying
    Su, Yin
    Shen, Nan
    Alexander, Jessy
    Guo, Jianping
    Ambrus, Julian
    Lin, Xin
    Yu, Di
    Sun, Xiaolin
    Li, Zhanguo
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01) : 141 - 149
  • [37] Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline A Pooled Analysis
    Tonstad, Serena
    Davies, Simon
    Flammer, Martina
    Russ, Cristina
    Hughes, John
    DRUG SAFETY, 2010, 33 (04) : 289 - 301
  • [38] Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of VareniclineA Pooled Analysis
    Serena Tonstad
    Simon Davies
    Martina Flammer
    Cristina Russ
    John Hughes
    Drug Safety, 2010, 33 : 289 - 301
  • [39] Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials
    Schoenfeld, P.
    Pimentel, M.
    Chang, L.
    Lembo, A.
    Chey, W. D.
    Yu, J.
    Paterson, C.
    Bortey, E.
    Forbes, W. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (10) : 1161 - 1168
  • [40] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
    Hassanien, M.
    Moshrif, A.
    Hetta, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 34 - 35
12345